Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Clin Gastroenterol Hepatol

Retrieve available abstracts of 226 articles:
HTML format



Single Articles


    December 2022
  1. GIRI S
    Cross-Sectional Imaging May Serve a Greater Purpose in Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2925.
    PubMed    


  2. BEELEN EMJ, Nieboer D, Arkenbosch JHC, Regueiro MD, et al
    Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials.
    Clin Gastroenterol Hepatol. 2022;20:2741-2752.
    PubMed     Abstract available


  3. MESERVE J, Ma C, Dulai PS, Jairath V, et al
    Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2022;20:2728-2740.
    PubMed     Abstract available


  4. BARNES EL, Kappelman MD, Zhang X, Long MD, et al
    Patients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis.
    Clin Gastroenterol Hepatol. 2022;20:2908-2910.
    PubMed     Abstract available


    November 2022
  5. ANDO Y, Yodoshi T, Yoshioka T
    Comment on "Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study".
    Clin Gastroenterol Hepatol. 2022 Nov 23:S1542-3565(22)01098.
    PubMed    


  6. BUISSON A, Nachury M, Fumery M
    Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Nov 16:S1542-3565(22)01084.
    PubMed    


  7. ALAYO Q, Deepak P
    Reply to Letter to the Editor: Inflammatory Bowel Disease and Incident Acute Arterial Events in the United Kingdom Biobank.
    Clin Gastroenterol Hepatol. 2022 Nov 12. pii: S1542-3565(22)01052.
    PubMed    


  8. PAPAMICHAEL K, Vande Casteele N, Abraham BP, Ritter T, et al
    Prior antibodies to infliximab or adalimumab are related to immunogenicity to vedolizumab in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Nov 10. pii: S1542-3565(22)01053.
    PubMed    


  9. SINGH S, Kim J, Luo J, Paul P, et al
    Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Clin Gastroenterol Hepatol. 2022 Nov 4:S1542-3565(22)01018.
    PubMed     Abstract available


  10. MAHMOUD R, Savelkoul EHJ, Jharap B, Oldenburg B, et al
    Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse- Authors' response.
    Clin Gastroenterol Hepatol. 2022 Nov 3. pii: S1542-3565(22)01017.
    PubMed    


  11. BALASUBRAMANIAM M, Nandi N, Aswani-Omprakash T, Sebastian S, et al
    Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia.
    Clin Gastroenterol Hepatol. 2022;20:2421-2426.
    PubMed    


  12. CARON B, Abreu MT, Siegel CA, Panaccione R, et al
    IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus.
    Clin Gastroenterol Hepatol. 2022;20:2619-2627.
    PubMed     Abstract available


  13. HANZEL J, Jairath V, Ma C, Guizzetti L, et al
    Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2598-2606.
    PubMed     Abstract available


  14. LEY D, Leroyer A, Dupont C, Sarter H, et al
    New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn's Disease: A Two-Decade Population-Based Study.
    Clin Gastroenterol Hepatol. 2022;20:2588-2597.
    PubMed     Abstract available


  15. GIRI S, Angadi S, Jearth V
    Deep Remission in Crohn's Disease: Optional or Quintessential.
    Clin Gastroenterol Hepatol. 2022;20:2654-2655.
    PubMed    


    October 2022
  16. THOMAS AS, Hanauer S, Wang Y
    Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Oct 18. pii: S1542-3565(22)00961.
    PubMed     Abstract available


  17. MEYER A, Dong C, Casagrande C, Chan S, et al
    Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study.
    Clin Gastroenterol Hepatol. 2022 Oct 12. pii: S1542-3565(22)00929.
    PubMed     Abstract available


  18. CHANG HC, Gau SY
    Inflammatory Bowel Disease and Incident Acute Arterial Events.
    Clin Gastroenterol Hepatol. 2022 Oct 8. pii: S1542-3565(22)00927.
    PubMed    


  19. CHENG D, Kochar BD, Cai T, Ananthakrishnan AN, et al
    Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor alpha Antagonists in Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:2366-2372.
    PubMed     Abstract available


  20. KOCHAR B, Jylhava J, Soderling J, Ritchie CS, et al
    Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Clin Gastroenterol Hepatol. 2022;20:2358-2365.
    PubMed     Abstract available


  21. D'HAENS G, Panes J, Louis E, Lacerda A, et al
    Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
    Clin Gastroenterol Hepatol. 2022;20:2337-2346.
    PubMed     Abstract available


  22. BACHOUR SP, Shah RS, Lyu R, Nakamura T, et al
    Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2327-2336.
    PubMed     Abstract available


    September 2022
  23. LITTLE RD, Ward MG, Sparrow MP
    Letter to the Editor: can subcutaneous infliximab replace dose-intensified intravenous administration in inflammatory bowel disease?
    Clin Gastroenterol Hepatol. 2022 Sep 22. pii: S1542-3565(22)00913.
    PubMed    


  24. DAI C, Jiang M, Huang YH
    Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00914.
    PubMed    


  25. HASHASH JG, Desai A, Kochhar GS, Farraye FA, et al
    Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in patients with Inflammatory Bowel Disease: A Propensity Matched Study.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00908.
    PubMed    


  26. PEYRIN-BIROULET L, Rahier JF, Kirchgesner J, Abitbol V, et al
    I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00916.
    PubMed     Abstract available


  27. ALAYO Q, Loftus EV Jr, Yarur A, Alvarado D, et al
    Inflammatory Bowel Disease is associated with an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank.
    Clin Gastroenterol Hepatol. 2022 Sep 5. pii: S1542-3565(22)00831.
    PubMed     Abstract available


  28. MAGRO F, Magalhaes D, Patita M, Arroja B, et al
    Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
    Clin Gastroenterol Hepatol. 2022;20:2059-2073.
    PubMed     Abstract available


  29. LAHARIE D, D'Haens G, Nachury M, Lambrecht G, et al
    Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
    Clin Gastroenterol Hepatol. 2022;20:2074-2082.
    PubMed     Abstract available


  30. FUDMAN DI, Perez-Reyes AE, Niccum BA, Melmed GY, et al
    Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review.
    Clin Gastroenterol Hepatol. 2022;20:1947-1970.
    PubMed     Abstract available


    August 2022
  31. MAHMOUD R, Savelkoul EHJ, Mares W, Goetgebuer R, et al
    Complete endoscopic healing is associated with a lower relapse risk after anti-TNF withdrawal in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Aug 30. pii: S1542-3565(22)00820.
    PubMed     Abstract available


  32. WHALEY KG, Xiong Y, Karns R, Hyams JS, et al
    MULTICENTER COHORT STUDY OF INFLIXIMAB PHARMACOKINETICS AND THERAPY RESPONSE IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS.
    Clin Gastroenterol Hepatol. 2022 Aug 25. pii: S1542-3565(22)00812.
    PubMed     Abstract available


  33. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2022 Aug 24. pii: S1542-3565(22)00811.
    PubMed     Abstract available


  34. STRAATMIJER T, van der Meulen AE, Duijvestein M
    Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons? Authors' reply.
    Clin Gastroenterol Hepatol. 2022 Aug 9. pii: S1542-3565(22)00739.
    PubMed    


  35. SAUK JS, Ryu HJ, Labus JS, Khandadash A, et al
    High Perceived Stress is Associated with Increased Risk of Ulcerative Colitis Clinical Flares.
    Clin Gastroenterol Hepatol. 2022 Aug 8. pii: S1542-3565(22)00721.
    PubMed     Abstract available


  36. DULAI PS, Feagan BG, Sands BE, Chen J, et al
    Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2022 Aug 4. pii: S1542-3565(22)00718.
    PubMed     Abstract available


  37. LONG MD, Weaver KN, Zhang X, Chun K, et al
    Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:1881-1883.
    PubMed     Abstract available


  38. OLLECH JE, Bannon L, Maharshak N, Bar N, et al
    Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease.
    Clin Gastroenterol Hepatol. 2022;20:1839-1846.
    PubMed     Abstract available


  39. KEEFER L, Gorbenko K, Siganporia T, Manning L, et al
    Resilience-based Integrated IBD Care Is Associated With Reductions in Health Care Use and Opioids.
    Clin Gastroenterol Hepatol. 2022;20:1831-1838.
    PubMed     Abstract available


  40. MA C
    To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:1668-1670.
    PubMed    


  41. PAUWELS RWM, van der Woude CJ, Nieboer D, Steyerberg EW, et al
    Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
    Clin Gastroenterol Hepatol. 2022;20:1671-1686.
    PubMed     Abstract available


    July 2022
  42. GUBATAN J, Barber GE, Nielsen OH, Juhl CB, et al
    Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2022 Jul 20. pii: S1542-3565(22)00675.
    PubMed     Abstract available


  43. BUIE MJ, Quan BKin J, Windsor JW, Coward S, et al
    Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21(st) Century: A Systematic Review with Temporal Analyses.
    Clin Gastroenterol Hepatol. 2022 Jul 18. pii: S1542-3565(22)00670.
    PubMed     Abstract available


  44. ALSOUD D, Verstockt B, Vermeire S
    Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?
    Clin Gastroenterol Hepatol. 2022 Jul 15. pii: S1542-3565(22)00656.
    PubMed    


  45. JENA A, James D, Singh AK, Dutta U, et al
    Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2022;20:1456-1479.
    PubMed     Abstract available


  46. AKIYAMA S, Rodriguez TG, Rubin DT
    Stratifying Risks of Ileal Pouch Outcomes.
    Clin Gastroenterol Hepatol. 2022;20:1620-1621.
    PubMed    


  47. NARULA N, Wong ECL, Dulai PS, Sengupta NK, et al
    Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:1579-1587.
    PubMed     Abstract available


  48. BATTAT R, Sandborn WJ
    Advances in the Comprehensive Management of Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:1436-1449.
    PubMed     Abstract available


    June 2022
  49. RIVIERE P, Bislenghi G, Vermeire S, Domenech E, et al
    Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques.
    Clin Gastroenterol Hepatol. 2022;20:1201-1204.
    PubMed    


  50. KOCHAR B, Pate V, Kappelman MD, Long MD, et al
    Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Clin Gastroenterol Hepatol. 2022;20:1299-1305.
    PubMed     Abstract available


  51. LIU Q, Zhang X, Ko HM, Stocker D, et al
    Constrictive and Hypertrophic Strictures in Ileal Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1292-e1304.
    PubMed     Abstract available


  52. DE GREGORIO M, Lee T, Krishnaprasad K, Amos G, et al
    Higher Anti-tumor Necrosis Factor-alpha Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
    Clin Gastroenterol Hepatol. 2022;20:1306-1314.
    PubMed     Abstract available


  53. FINK M, Simons M, Tomasino K, Pandit A, et al
    When Is Patient Behavior Indicative of Avoidant Restrictive Food Intake Disorder (ARFID) Vs Reasonable Response to Digestive Disease?
    Clin Gastroenterol Hepatol. 2022;20:1241-1250.
    PubMed     Abstract available


    May 2022
  54. STRAATMIJER T, Biemans VB, Visschedijk M, Hoentjen F, et al
    Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF experienced ulcerative colitis patients: a nationwide Dutch Registry study.
    Clin Gastroenterol Hepatol. 2022 May 26. pii: S1542-3565(22)00510.
    PubMed     Abstract available


  55. OZEKI K, Tanida S, Kataoka H
    Aseptic abscess syndrome with ulcerative colitis and pyoderma gangrenosum.
    Clin Gastroenterol Hepatol. 2022 May 25. pii: S1542-3565(22)00512.
    PubMed    


  56. SCHWARTZ DA, Peyrin-Biroulet L, Lasch K, Adsul S, et al
    Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
    Clin Gastroenterol Hepatol. 2022;20:1059-1067.
    PubMed     Abstract available


  57. DULAI PS, Wong ECL, Reinisch W, Narula N, et al
    Clinical Decision Support Tool for Infliximab in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1192-e1195.
    PubMed     Abstract available


  58. AHN HJ, Kim YJ, Lee HS, Park JH, et al
    High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:e1022-e1039.
    PubMed     Abstract available


  59. KAWAMOTO A, Takenaka K, Hibiya S, Ohtsuka K, et al
    Serum Leucine-Rich alpha2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1196-e1200.
    PubMed     Abstract available


  60. SCHAEFER M, Laurent V, Grandmougin A, Vuitton L, et al
    A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index.
    Clin Gastroenterol Hepatol. 2022;20:e1040-e1049.
    PubMed     Abstract available


  61. HUANG X, Li X
    Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1216.
    PubMed    


  62. QUINN KP, Urquhart SA, Janssens LP, Lennon RJ, et al
    Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype.
    Clin Gastroenterol Hepatol. 2022;20:e964-e973.
    PubMed     Abstract available


    April 2022
  63. COHEN NA, Choi D, Choden T, Cleveland NK, et al
    Ozanimod in the Treatment of Ulcerative Colitis: Initial Real World Data from A Large Tertiary Center.
    Clin Gastroenterol Hepatol. 2022 Apr 2. pii: S1542-3565(22)00310.
    PubMed    


  64. STEINER CA, Berinstein JA, Louissaint J, Higgins PDR, et al
    Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.
    Clin Gastroenterol Hepatol. 2022;20:817-846.
    PubMed     Abstract available


  65. ALLOCCA M, Craviotto V, Bonovas S, Furfaro F, et al
    Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study.
    Clin Gastroenterol Hepatol. 2022;20:e723-e740.
    PubMed     Abstract available


  66. CALABRESE E, Rispo A, Zorzi F, De Cristofaro E, et al
    Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study.
    Clin Gastroenterol Hepatol. 2022;20:e711-e722.
    PubMed     Abstract available


  67. BLACKWELL J, Saxena S, Jayasooriya N, Petersen I, et al
    Stoma Formation in Crohn's Disease and the Likelihood of Antidepressant Use: A Population-Based Cohort Study.
    Clin Gastroenterol Hepatol. 2022;20:e703-e710.
    PubMed     Abstract available


    March 2022
  68. SONNENBERG A, Turner KO, Saboorian H, Singhal A, et al
    The Occurrence of Gastritis in Microscopic Colitis and Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Mar 23. pii: S1542-3565(22)00294.
    PubMed    


  69. ANYANE-YEBOA A, Quezada S, Rubin DT, Balzora S, et al
    The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Mar 17. pii: S1542-3565(22)00285.
    PubMed     Abstract available


  70. VEYRARD P, Pellet G, Laharie D, Nachury M, et al
    Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis.
    Clin Gastroenterol Hepatol. 2022 Mar 17. pii: S1542-3565(22)00282.
    PubMed    


  71. DANESE S, Sands BE, Abreu MT, O'Brien CD, et al
    Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial.
    Clin Gastroenterol Hepatol. 2022 Mar 8. pii: S1542-3565(22)00207.
    PubMed     Abstract available


  72. BEN-HORIN S, Har-Noy O, Katsanos KH, Roblin X, et al
    Corticosteroids and 5-ASA versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial.
    Clin Gastroenterol Hepatol. 2022 Mar 7. pii: S1542-3565(22)00213.
    PubMed     Abstract available


  73. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Earlier Anti-TNF Initiation Leads to Long Term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2022 Mar 2. pii: S1542-3565(22)00147.
    PubMed     Abstract available


  74. PUDIPEDDI A, Paramsothy S, Leong RW
    Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?
    Clin Gastroenterol Hepatol. 2022;20:e640-e641.
    PubMed    


  75. ATIA O, Asayag N, Focht G, Lujan R, et al
    Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epiIIRN Cohort.
    Clin Gastroenterol Hepatol. 2022;20:e484-e495.
    PubMed     Abstract available


  76. SANDBORN WJ, Rebuck R, Wang Y, Zou B, et al
    Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
    Clin Gastroenterol Hepatol. 2022;20:578-590.
    PubMed     Abstract available


  77. GUILLO L, Rabaud C, Choy EH, D'Amico F, et al
    Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide.
    Clin Gastroenterol Hepatol. 2022;20:481-490.
    PubMed     Abstract available


    February 2022
  78. KIM HS, Hernaez R, Sansgiry S, Waljee AK, et al
    Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Feb 28. pii: S1542-3565(22)00205.
    PubMed     Abstract available


  79. RODRIGUEZ-DUQUE JC, Calleja JL, Iruzubieta P, Hernandez-Conde M, et al
    Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors.
    Clin Gastroenterol Hepatol. 2022 Feb 3. pii: S1542-3565(22)00093.
    PubMed     Abstract available


  80. HUANG X, Li X
    Predictive Value of Bowel Ultrasound in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e345-e346.
    PubMed    


  81. HUNTER JO
    Dietary Treatment of Crohn's Disease in Adults.
    Clin Gastroenterol Hepatol. 2022;20:e343.
    PubMed    


  82. NG A
    Maintenance Therapy in Crohn's Disease: Does the Drug Matter?
    Clin Gastroenterol Hepatol. 2022;20:472-473.
    PubMed    


  83. KAYAL M, Ungaro RC, Colombel JF
    The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus.
    Clin Gastroenterol Hepatol. 2022;20:281-282.
    PubMed    


  84. LUCAS UEMURA K, Sousa Freitas Queiroz N, Lees CW
    What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease?
    Clin Gastroenterol Hepatol. 2022;20:468-469.
    PubMed    


  85. SINGH S, Heien HC, Herrin J, Dulai PS, et al
    Comparative Risk of Serious Infections With Tumor Necrosis Factor alpha Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:e74-e88.
    PubMed     Abstract available


  86. VANDE CASTEELE N, Abreu MT, Flier S, Papamichael K, et al
    Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
    Clin Gastroenterol Hepatol. 2022;20:465-467.
    PubMed     Abstract available


  87. BROCHARD C, Rabilloud ML, Hamonic S, Bajeux E, et al
    Natural History of Perianal Crohn's Disease: Long-term Follow-up of a Population-Based Cohort.
    Clin Gastroenterol Hepatol. 2022;20:e102-e110.
    PubMed     Abstract available


  88. KAMBOJ AK, Kane SV, Leggett CL
    Crohn's Disease of the Esophagus.
    Clin Gastroenterol Hepatol. 2022;20:A15-A16.
    PubMed    


    January 2022
  89. MAHMOUD R, Schultheiss JPD, Louwers JM, van der Kaaij MT, et al
    Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Jan 28. pii: S1542-3565(22)00073.
    PubMed     Abstract available


  90. LOPES EW, Lochhead P, Burke KE, Richter JM, et al
    Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype.
    Clin Gastroenterol Hepatol. 2022 Jan 11. pii: S1542-3565(22)00026.
    PubMed     Abstract available


  91. FREY S, Chowdhury R, Connolly CM, Werbel WA, et al
    Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Jan 5. pii: S1542-3565(22)00003.
    PubMed    


  92. KAWADA T
    Stoma Formation and Antidepressant Use in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:245-246.
    PubMed    


  93. HANZEL J, Ma C, Zou G, Singh S, et al
    Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT.
    Clin Gastroenterol Hepatol. 2022;20:236-238.
    PubMed     Abstract available


  94. HASHASH JG, Knisely MR, Germain A, McAuliff K, et al
    Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study.
    Clin Gastroenterol Hepatol. 2022;20:96-104.
    PubMed     Abstract available


  95. ALMUHAIDB A, Sina J, Chen CH
    Unusual Presentation of a Crohn's Disease Patient: Not Your Typical Flare.
    Clin Gastroenterol Hepatol. 2022;20:e5-e6.
    PubMed    


    December 2021
  96. KAKUTA Y, Shirai T, McGovern DPB, Braun J, et al
    Novel diagnostic autoantibodies against Endothelial Protein C Receptor in patients with ulcerative colitis.
    Clin Gastroenterol Hepatol. 2021 Dec 28. pii: S1542-3565(21)01359.
    PubMed    


  97. LEV-TZION R, Focht G, Lujan R, Mendelovici A, et al
    COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation.
    Clin Gastroenterol Hepatol. 2021 Dec 23. pii: S1542-3565(21)01350.
    PubMed     Abstract available


  98. CHARILAOU P, Tricarico C, Battat R, Scherl EJ, et al
    Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS CoV-2 Vaccination.
    Clin Gastroenterol Hepatol. 2021 Dec 8. pii: S1542-3565(21)01301.
    PubMed    


  99. SCHELL TL, Richard LJ, Tippins K, Russ RK, et al
    High but Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Dec 8. pii: S1542-3565(21)01308.
    PubMed    


  100. BAMIAS G, Cominelli F
    Exploring the Early Phase of Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:2469-2480.
    PubMed     Abstract available


  101. SHAFER LA, Sofia MA, Rubin DT, Steinhart AH, et al
    An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI.
    Clin Gastroenterol Hepatol. 2021;19:2524-2531.
    PubMed     Abstract available


    November 2021
  102. LUKIN DJ, Funez-dePagnier G, Lima S, Lai D, et al
    No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.
    Clin Gastroenterol Hepatol. 2021;19:2312-2314.
    PubMed    


  103. DEBNATH P, Rathi P
    Treat to Target in Patients with Ileocolonic Crohn's Disease: Endoscopic Remission or Histologic Healing?
    Clin Gastroenterol Hepatol. 2021;19:2452.
    PubMed    


  104. COHEN-MEKELBURG S, Yu X, Costa D, Hofer TP, et al
    Variation in Provider Connectedness Associates With Outcomes of Inflammatory Bowel Diseases in an Analysis of Data From a National Health System.
    Clin Gastroenterol Hepatol. 2021;19:2302-2311.
    PubMed     Abstract available


    October 2021
  105. KUMAR R, Zaghiyan K, Ha C
    Lower Surgical Risks in "Contemporary" IBD Cohorts: A Reflection of Better Quality of Care or Statistics?
    Clin Gastroenterol Hepatol. 2021;19:2029-2030.
    PubMed    


  106. DEBNATH P, Rathi P
    Outcomes Related to Mucosal Healing in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:2214.
    PubMed    


  107. FENSTER M, Alayo QA, Khatiwada A, Wang W, et al
    Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
    Clin Gastroenterol Hepatol. 2021;19:2207-2209.
    PubMed     Abstract available


  108. QIAN AS, Nguyen NH, Elia J, Ohno-Machado L, et al
    Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:2054-2063.
    PubMed     Abstract available


  109. SCOTT FI, Hans AK, Gerich ME, Fennimore B, et al
    Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:2082-2092.
    PubMed     Abstract available


  110. SOH H, Lee HJ, Han K, Park S, et al
    Atopic Diseases Are Associated With Development of Inflammatory Bowel Diseases in Korea: A Nationwide Population-based Study.
    Clin Gastroenterol Hepatol. 2021;19:2072-2081.
    PubMed     Abstract available


    September 2021
  111. GUPTA A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN, et al
    Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:1800-1813.
    PubMed     Abstract available


  112. PLEVRIS N, Fulforth J, Lyons M, Siakavellas SI, et al
    Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:1835-1844.
    PubMed     Abstract available


  113. HAMDEH S, Micic D, Hanauer S
    Drug-Induced Colitis.
    Clin Gastroenterol Hepatol. 2021;19:1759-1779.
    PubMed     Abstract available


    August 2021
  114. PUGLIESE D, Privitera G, Schepis T, Larosa L, et al
    Drug-related pneumonitis in patients receiving Vedolizumab therapy for Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Aug 31. pii: S1542-3565(21)00921.
    PubMed    


  115. LO CH, Khandpur N, Rossato SL, Lochhead P, et al
    Ultra-processed foods and risk of Crohn's disease and ulcerative colitis: a prospective cohort study.
    Clin Gastroenterol Hepatol. 2021 Aug 27. pii: S1542-3565(21)00911.
    PubMed     Abstract available


  116. BERINSTEIN JA, Cohen-Mekelburg SA, Greenberg GM, Wray D, et al
    A Care Coordination Intervention Improves Symptoms but not Charges in High-Risk Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Aug 27. pii: S1542-3565(21)00914.
    PubMed     Abstract available


  117. WONG ECL, Colombel JF, Riddell R, Marshall JK, et al
    Epithelial Neutrophilic Infiltrate - The Rising Star in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Aug 20. pii: S1542-3565(21)00904.
    PubMed    


  118. SASSON AN, Sheehan G, Yu A, Gupta A, et al
    Yield and Predictors of surveillance colonoscopies in older adults with long-standing ulcerative colitis.
    Clin Gastroenterol Hepatol. 2021 Aug 20. pii: S1542-3565(21)00899.
    PubMed     Abstract available


  119. D'SILVA A, Fox DE, Raman M
    This Letter to the Editor is in response to: Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease/Dr. Maitreyi Raman.
    Clin Gastroenterol Hepatol. 2021 Aug 16. pii: S1542-3565(21)00874.
    PubMed    


  120. YELENCICH E, Truong E, Widaman AM, Pignotti G, et al
    Avoidant Restrictive Food Intake Disorder Prevalent among Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Aug 10. pii: S1542-3565(21)00864.
    PubMed     Abstract available


  121. ESTEVINHO MM, Magro F
    Epithelial neutrophilic infiltrate - the rising star in ulcerative colitis.
    Clin Gastroenterol Hepatol. 2021 Aug 5. pii: S1542-3565(21)00835.
    PubMed    


  122. DALAL RS, McClure E, Marcus J, Winter RW, et al
    COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:1730-1732.
    PubMed     Abstract available


  123. YANAI H, Goren I, Godny L, Maharshak N, et al
    Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
    Clin Gastroenterol Hepatol. 2021;19:1564-1572.
    PubMed     Abstract available


  124. DE BRUYN JR, Bossuyt P, Ferrante M, West RL, et al
    High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial.
    Clin Gastroenterol Hepatol. 2021;19:1573-1582.
    PubMed     Abstract available


    July 2021
  125. RUDRA S, Shaul E, Conrad M, Patel T, et al
    Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset- Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 27. pii: S1542-3565(21)00822.
    PubMed    


  126. NARULA N, Wong ECL, Marshall JK, Colombel JF, et al
    Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Jul 27. pii: S1542-3565(21)00820.
    PubMed     Abstract available


  127. DAI C, Jiang M, Huang YH
    Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 21. pii: S1542-3565(21)00759.
    PubMed    


  128. MEYER A, Taine M, Drouin J, Weill A, et al
    Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-TNF.
    Clin Gastroenterol Hepatol. 2021 Jul 20. pii: S1542-3565(21)00760.
    PubMed     Abstract available


  129. KHAN N, Wang L, Trivedi C, Pernes T, et al
    Efficacy of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 15. pii: S1542-3565(21)00754.
    PubMed     Abstract available


  130. CHAN SSM, Chen Y, Casey K, Olen O, et al
    Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: A pooled analysis of five prospective cohort studies.
    Clin Gastroenterol Hepatol. 2021 Jul 6. pii: S1542-3565(21)00720.
    PubMed     Abstract available


  131. NARULA N, Wong ECL, Colombel JF, Riddell R, et al
    Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Jul 3. pii: S1542-3565(21)00716.
    PubMed     Abstract available


  132. RODRIGUEZ-LAGO I, Barreiro-de Acosta M
    Look at Both Sides of the Coin in Determining Risk of Complicated Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:1503-1504.
    PubMed    


  133. SEDANO R, Guizzetti L, McDonald C, Jairath V, et al
    Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
    Clin Gastroenterol Hepatol. 2021;19:1497-1498.
    PubMed     Abstract available


  134. KAYAL M, Lambin T, Plietz M, Rizvi A, et al
    Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure.
    Clin Gastroenterol Hepatol. 2021;19:1491-1493.
    PubMed     Abstract available


  135. HU A, Kotze PG, Burgevin A, Tan W, et al
    Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Clin Gastroenterol Hepatol. 2021;19:1366-1376.
    PubMed     Abstract available


  136. NGUYEN NH, Khera R, Ohno-Machado L, Sandborn WJ, et al
    Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:1377-1386.
    PubMed     Abstract available


  137. MILLIEN V, Abrams D, Khalaf N
    Not All Terminal Ileitis Is Crohn's Disease: Intestinal Tuberculosis Causing Small Bowel Obstruction.
    Clin Gastroenterol Hepatol. 2021;19:e71.
    PubMed    


    June 2021
  138. D'SILVA A, Fox DE, Nasser Y, Vallance JK, et al
    Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review with Meta-analysis.
    Clin Gastroenterol Hepatol. 2021 Jun 30. pii: S1542-3565(21)00698.
    PubMed     Abstract available


  139. ASSCHER VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, et al
    Deficits in geriatric assessment associate with disease activity and -burden in older patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jun 18. pii: S1542-3565(21)00643.
    PubMed     Abstract available


  140. CASSINOTTI A, Corona A, Duca P, Nebuloni M, et al
    NON INVASIVE MONITORING AFTER AZATHIOPRINE WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN DEEP REMISSION.
    Clin Gastroenterol Hepatol. 2021 Jun 14. pii: S1542-3565(21)00642.
    PubMed     Abstract available


  141. DANESE S, Klopocka M, Scherl EJ, Romatowski J, et al
    Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].
    Clin Gastroenterol Hepatol. 2021 Jun 11. pii: S1542-3565(21)00614.
    PubMed     Abstract available


  142. AGRAWAL M, Brenner EJ, Yan Mak JW, Zhang X, et al
    COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States.
    Clin Gastroenterol Hepatol. 2021 Jun 2. pii: S1542-3565(21)00599.
    PubMed    


  143. FAHAD H, Dulai PS, Shen B, Kochhar GS, et al
    Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications.
    Clin Gastroenterol Hepatol. 2021;19:1288-1291.
    PubMed     Abstract available


  144. BRAGA NETO MB, Ramos GP, Loftus EV Jr, Faubion WA, et al
    Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
    Clin Gastroenterol Hepatol. 2021;19:1285-1287.
    PubMed     Abstract available


  145. POUILLON L, Remen T, Amicone C, Louis E, et al
    Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
    Clin Gastroenterol Hepatol. 2021;19:1218-1225.
    PubMed     Abstract available


  146. VANDE CASTEELE N, Jairath V, Jeyarajah J, Dulai PS, et al
    Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab.
    Clin Gastroenterol Hepatol. 2021;19:1209-1217.
    PubMed     Abstract available


  147. HU AB, Tan W, Deshpande V, Ananthakrishnan AN, et al
    Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission.
    Clin Gastroenterol Hepatol. 2021;19:1226-1233.
    PubMed     Abstract available


  148. LAGRANGE J, Lacolley P, Wahl D, Peyrin-Biroulet L, et al
    Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:1088-1097.
    PubMed     Abstract available


    May 2021
  149. TROELSEN FS, Sorensen HT, Crockett SD, Pedersen L, et al
    Characteristics and survival of patients with inflammatory bowel disease and post-colonoscopy colorectal cancers.
    Clin Gastroenterol Hepatol. 2021 May 26. pii: S1542-3565(21)00577.
    PubMed     Abstract available


  150. BERINSTEIN JA, Sheehan J, Dias M, Berinstein EM, et al
    Tofacitinib for Biologic-Experienced Hospitalized Patients with Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
    Clin Gastroenterol Hepatol. 2021 May 25. pii: S1542-3565(21)00576.
    PubMed     Abstract available


  151. KAYAL M, Ungaro RC, Riggs A, Kamal K, et al
    Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.
    Clin Gastroenterol Hepatol. 2021 May 22. pii: S1542-3565(21)00571.
    PubMed     Abstract available


  152. AHMED W, Scott FI
    Closing the gap: the real-world risk of serious infections with vedolizumab in comparison to anti-TNF therapy in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 May 19. pii: S1542-3565(21)00564.
    PubMed    


  153. CONSTANT BD, Dutmer CM, Arnold MA, Hall C, et al
    Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult to Treat Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 May 6. pii: S1542-3565(21)00504.
    PubMed    


  154. CON D, Van Langenberg DR, Vasudevan A
    Response to: Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection.
    Clin Gastroenterol Hepatol. 2021;19:1077.
    PubMed    


  155. SAGAMI S, Kobayashi T, Miyatani Y, Okabayashi S, et al
    Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:908-921.
    PubMed     Abstract available


  156. BOSSUYT P, Dreesen E, Rimola J, Devuysere S, et al
    Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:947-954.
    PubMed     Abstract available


  157. SINGER AAM, Bloom DA, Adler J
    Factors Associated With Development of Perianal Fistulas in Pediatric Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:1071-1073.
    PubMed     Abstract available


    April 2021
  158. CON D, Vasudevan A, van Langenberg DR
    Predictive Scores in Acute Severe Ulcerative Colitis: Which, What and When are the Decision Points We Should Target?
    Clin Gastroenterol Hepatol. 2021 Apr 24. pii: S1542-3565(21)00469.
    PubMed    


  159. VOLGER S, Scherl E
    Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy.
    Clin Gastroenterol Hepatol. 2021 Apr 14. pii: S1542-3565(21)00449.
    PubMed    


  160. ROTH K, Berinstein JA
    Reply: A Patient Perspective on Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021 Apr 8. pii: S1542-3565(21)00446.
    PubMed    


  161. BHATTACHARYA S, Marciano BE, Malech HL, Quezado M, et al
    Safety and efficacy of ustekinumab in the inflammatory bowel disease of chronic granulomatous disease.
    Clin Gastroenterol Hepatol. 2021 Apr 1. pii: S1542-3565(21)00349.
    PubMed    


  162. SORRENTINO D, Geraci M, Kuballa A
    Diagnosis of Preclinical Crohn's Disease: Hurdles, Challenges, and Hopes.
    Clin Gastroenterol Hepatol. 2021;19:857-858.
    PubMed    


  163. YZET C, Diouf M, Singh S, Brazier F, et al
    No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:668-679.
    PubMed     Abstract available


  164. SIGALL BONEH R, Van Limbergen J, Wine E, Assa A, et al
    Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:752-759.
    PubMed     Abstract available


  165. RIVIERE P, Vermeire S, Irles-Depe M, Van Assche G, et al
    Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.
    Clin Gastroenterol Hepatol. 2021;19:713-720.
    PubMed     Abstract available


  166. JESSEN B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, et al
    Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.
    Clin Gastroenterol Hepatol. 2021;19:721-731.
    PubMed     Abstract available


  167. BARNES EL, Kochar B, Herfarth HH, Winter RW, et al
    Creation of a Case-Finding Definition for Identifying Patients With Acute Pouchitis in Administrative Claims Data.
    Clin Gastroenterol Hepatol. 2021;19:842-844.
    PubMed     Abstract available


    March 2021
  168. AHMED W, Galati J, Kumar A, Christos PJ, et al
    Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2021 Mar 30. pii: S1542-3565(21)00344.
    PubMed     Abstract available


  169. LOPES EW, Lebwohl B, Burke KE, Ivey KL, et al
    DIETARY GLUTEN INTAKE IS NOT ASSOCIATED WITH RISK OF INFLAMMATORY BOWEL DISEASE IN U.S. ADULTS WITHOUT CELIAC DISEASE.
    Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00339.
    PubMed     Abstract available


  170. DALAL RS, Esckilsen S, Barnes EL, Pruce JC, et al
    Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study.
    Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00338.
    PubMed    


  171. NAMBU R, Warner N, Mulder DJ, Kotlarz D, et al
    A Systematic Review of Monogenic Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Mar 18. pii: S1542-3565(21)00331.
    PubMed     Abstract available


  172. OKAMOTO T, Fukuda K
    Long-term outcomes in asymptomatic ulcerative colitis diagnosed during screening colonoscopy.
    Clin Gastroenterol Hepatol. 2021 Mar 11. pii: S1542-3565(21)00275.
    PubMed    


  173. SANDBORN WJ, Peyrin-Biroulet L, Sharara AI, Su C, et al
    Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Clin Gastroenterol Hepatol. 2021 Mar 5. pii: S1542-3565(21)00222.
    PubMed     Abstract available


  174. ALAMEEL T, Al Sulais E
    Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection.
    Clin Gastroenterol Hepatol. 2021;19:621-622.
    PubMed    


  175. ANANTHAKRISHNAN AN, Deshpande V
    It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD.
    Clin Gastroenterol Hepatol. 2021;19:446-447.
    PubMed    


  176. TANDON P, Malhi G, Abdali D, Pogue E, et al
    Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn's Recurrence: Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:451-462.
    PubMed     Abstract available


  177. BORREN NZ, Plichta D, Joshi AD, Bonilla G, et al
    Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:519-527.
    PubMed     Abstract available


  178. SASSON AN, Ananthakrishnan AN, Raman M
    Diet in Treatment of Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:425-435.
    PubMed     Abstract available


    February 2021
  179. AKHTAR HJ, Nguyen TM, Ma C, Jairath V, et al
    Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy.
    Clin Gastroenterol Hepatol. 2021 Feb 19. pii: S1542-3565(21)00204.
    PubMed    


  180. JANGI S, Holmer AK, Dulai PS, Boland B, et al
    Spatial Evolution of Histologic and Endoscopic Healing in Left and Right Colon in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Feb 5. pii: S1542-3565(21)00108.
    PubMed     Abstract available


  181. AKIYAMA S, Ollech JE, Rai V, Glick LR, et al
    Endoscopic phenotype of the J pouch in patients with inflammatory bowel disease: A new classification for pouch outcomes.
    Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00111.
    PubMed     Abstract available


  182. LONG MD, Siegel CA, Abraham BP, Chiorean M, et al
    Day Care Attendance and Infectious Complications in Children Born to Mothers with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00104.
    PubMed    


  183. FALECK DM, Shmidt E, Huang R, Katta LG, et al
    Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:238-245.
    PubMed     Abstract available


  184. BOLAND K, Bedrani L, Turpin W, Kabakchiev B, et al
    Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis.
    Clin Gastroenterol Hepatol. 2021;19:296-304.
    PubMed     Abstract available


  185. LANDEMAINE A, Petitcollin A, Brochard C, Miard C, et al
    Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection.
    Clin Gastroenterol Hepatol. 2021;19:288-295.
    PubMed     Abstract available


    January 2021
  186. LAURAIN PA, Guillo L, D'Amico F, Netter P, et al
    Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study.
    Clin Gastroenterol Hepatol. 2021 Jan 22. pii: S1542-3565(21)00078.
    PubMed     Abstract available


  187. VAN DER SLOOT KWJ, Tiems JL, Visschedijk MC, Festen EAM, et al
    Cigarette smoke increases risk for colorectal neoplasia in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jan 13. pii: S1542-3565(21)00018.
    PubMed     Abstract available


  188. DAI C, Huang YH, Jiang M
    Two Types of Fecal Tests in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021;19:209.
    PubMed    


  189. DEL HOYO J, Aguas M
    Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
    Clin Gastroenterol Hepatol. 2021;19:206-207.
    PubMed    


  190. BRENNER EJ, Kappelman MD
    Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:210-211.
    PubMed    


  191. NAGANUMA M, Kanai T
    Reply.
    Clin Gastroenterol Hepatol. 2021;19:209-210.
    PubMed    


  192. LO CH, Khalili H, Song M, Lochhead P, et al
    Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:87-95.
    PubMed     Abstract available


  193. OLLECH JE, Normatov I, Peleg N, Wang J, et al
    Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:104-110.
    PubMed     Abstract available


  194. HANZEL J, Zdovc J, Kurent T, Sever N, et al
    Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
    Clin Gastroenterol Hepatol. 2021;19:111-118.
    PubMed     Abstract available


    December 2020
  195. KIRCHGESNER J, Desai RJ, Beaugerie L, Schneeweiss S, et al
    Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2020 Dec 30. pii: S1542-3565(20)31726.
    PubMed     Abstract available


  196. GUILLO L, Uzzan M, Beaugerie L, Gornet JM, et al
    Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.
    Clin Gastroenterol Hepatol. 2020 Dec 24. pii: S1542-3565(20)31719.
    PubMed     Abstract available


  197. KHANNA R, Ma C, Jairath V, Casteele NV, et al
    Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.
    Clin Gastroenterol Hepatol. 2020 Dec 15. pii: S1542-3565(20)31674.
    PubMed     Abstract available


  198. MA C, Jeyarajah J, Guizzetti L, Parker CE, et al
    Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Dec 3. pii: S1542-3565(20)31630.
    PubMed     Abstract available


    November 2020
  199. WANG CY, Chen WL, Cheng-Chung Wei J
    Link Between Inflammatory Bowel Disease and Risk of Chronic Kidney Disease.
    Clin Gastroenterol Hepatol. 2020 Nov 21. pii: S1542-3565(20)31498.
    PubMed    


  200. VAJRAVELU RK, Copelovitch L, Denburg MR
    Letter title: "Link between inflammatory bowel disease and risk of chronic kidney disease" by Wang and colleagues.
    Clin Gastroenterol Hepatol. 2020 Nov 20. pii: S1542-3565(20)31565.
    PubMed    


  201. BRAAT H, Parikh K, Peppelenbosch MP
    Complete Resolution of Mucosal Neutrophils May Predict Non-fatigue in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Nov 19. pii: S1542-3565(20)31559.
    PubMed    


  202. GRACIE DJ, Ford AC
    Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?
    Clin Gastroenterol Hepatol. 2020 Nov 6. pii: S1542-3565(20)31434.
    PubMed    


  203. D'AMICO F, Danese S, Peyrin-Biroulet L
    Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
    Clin Gastroenterol Hepatol. 2020;18:2689-2700.
    PubMed     Abstract available


    October 2020
  204. SANDBORN WJ, Peyrin-Biroulet L, Quirk D, Wang W, et al
    Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31496.
    PubMed     Abstract available


  205. TSAI L, Ma C, Dulai PS, Prokop LJ, et al
    Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts.
    Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31497.
    PubMed     Abstract available


  206. OLLECH JE, Avni-Biron I, Glick L, Haider H, et al
    Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated with Good Maternal and Fetal Outcomes.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31493.
    PubMed     Abstract available


  207. LI YM, Stettler I, Oungpasuk K
    Association Between Provider Connectedness and Inflammatory Bowel Disease Outcomes.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31291.
    PubMed    


  208. STEENHOLDT C, Jensen JT, Brynskov J, Moller AM, et al
    Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31495.
    PubMed     Abstract available


  209. VEDAMURTHY A, Gangasani N, Ananthakrishnan AN
    Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31396.
    PubMed     Abstract available


  210. KHOUDARI G, Mansoor E, Click B, Alkhayyat M, et al
    Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients after Initiation of Biologics: A Cohort Study.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31397.
    PubMed     Abstract available


  211. NAESSENS D, Cameron C, Hoaglin DC
    Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31428.
    PubMed    


  212. BRENNER EJ, Pigneur B, Focht G, Zhang X, et al
    BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES.
    Clin Gastroenterol Hepatol. 2020 Oct 12. pii: S1542-3565(20)31399.
    PubMed    


  213. COLOMBEL JF, Osterman MT, Thorpe AJ, Salese L, et al
    Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31389.
    PubMed     Abstract available


  214. LUKIN D, Faleck D, Xu R, Zhang Y, et al
    Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31388.
    PubMed     Abstract available


    September 2020
  215. KIM HJ, Shah SC, Hann HJ, Kazmi SZ, et al
    Familial Risk of Inflammatory Bowel Disease - A Population-based Cohort study in South Korea.
    Clin Gastroenterol Hepatol. 2020 Sep 30. pii: S1542-3565(20)31384.
    PubMed     Abstract available


  216. DIMKE H, Winther-Jensen M, Allin KH, Lund L, et al
    Risk of Urolithiasis in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Sep 29. pii: S1542-3565(20)31379.
    PubMed     Abstract available


    August 2020
  217. STORAN D, Doherty GA, Cullen G
    Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Aug 30. pii: S1542-3565(20)31079.
    PubMed    


  218. GILMORE R, Hilley P, Srinivasan A, Choy MC, et al
    Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 16. pii: S1542-3565(20)31008.
    PubMed    


  219. BERINSTEIN JA, Steiner CA, Higgins PDR
    Reply to Tofacitinib is safe and effective when used in combination with Infliximab for the management of Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 12. pii: S1542-3565(20)31132.
    PubMed    


    July 2020
  220. AREBI N, Dyall L, Kamperidis N
    A User's Guide to De-Escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jul 27. pii: S1542-3565(20)30920.
    PubMed    


    June 2020
  221. SCAIOLI E, Salice M, Belluzzi A
    Omega-3 as a Part of the Dietary Guidance for Patients with Ulcerative Colitis: Beyond the Natural Sources.
    Clin Gastroenterol Hepatol. 2020 Jun 25. pii: S1542-3565(20)30760.
    PubMed    


  222. PAPAMICHAEL K, Cheifetz AS
    Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jun 5. pii: S1542-3565(20)30638.
    PubMed    


    April 2020
  223. ONA S, Long M, Mitchell C
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:1002.
    PubMed    


    February 2020
  224. PANSART C, Roblin X, Paul S
    Preanalytical Heterogeneity in Fecal Calprotectin Measurement Needs To Be Considered for Tight Control.
    Clin Gastroenterol Hepatol. 2020;18:524-525.
    PubMed    


  225. KENNEDY NA, Lees CW
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:526.
    PubMed    


  226. COZIJNSEN MA, Turner D
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:525-526.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: